Lyndra Therapeutics is a biotechnology company focused on developing ultra-long-acting oral medications designed to replace daily pill regimens. By providing sustained-release therapies that can be administered weekly or even monthly, the company aims to enhance medication adherence and improve health outcomes. Their innovative approach includes polypill strategies that consolidate multiple medications into a single dose, thereby increasing safety and efficacy while potentially reducing overall healthcare costs. Lyndra Therapeutics is actively developing treatments for a range of conditions, including Alzheimer's disease, cardiovascular and metabolic disorders, psychiatric conditions, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. Established in 2015 and headquartered in Watertown, Massachusetts, the company seeks to make a significant impact on global health through its advanced therapeutic solutions.
Volastra Therapeutics, Inc., a biotechnology company, develops therapies for the treatment of metastatic cancers. The company offers a library of organoids derived from metastatic cancer samples to elucidate how tumors spread and devise therapeutic strategies that target chromosomal instability during the process of cancer metastasis. Volastra Therapeutics, Inc. was incorporated in 2019 and is based in New York, New York.
CalciMedica, Inc. is a biotechnology company based in La Jolla, California, focused on the discovery and development of small molecule drugs aimed at treating autoimmune and inflammatory diseases. Founded in December 2006 by a team of scientists with backgrounds in calcium signaling, the company specializes in the targeted inhibition of calcium release-activated calcium channels, a key mechanism in immune response regulation. The founding team includes individuals who previously collaborated at TorreyPines Therapeutics and the CBR Institute, where they made significant contributions to understanding calcium signaling pathways. Through its innovative research, CalciMedica aims to develop effective therapies for patients suffering from various autoimmune conditions.
V-Wave Ltd. is a medical technology company based in Caesarea, Israel, with additional offices in the United States. Founded in 2009, it specializes in the development of percutaneous implantable therapeutic devices aimed at treating chronic heart failure (HF) patients, which is a major cause of morbidity and mortality worldwide. The company has created the V-Wave Shunt, a biocompatible inter-atrial unidirectional implant designed for patients with both preserved and reduced ejection fractions, addressing the needs of those who experience disabling symptoms despite optimal medical therapy. V-Wave's innovative approach focuses on relieving symptoms, reducing hospitalizations, enhancing exercise capacity, and improving overall quality of life for HF patients. The organization is backed by a team of experienced engineers and medical scientists who have a proven track record in developing and bringing various implantable cardiovascular devices to market.
EnClear Therapies, Inc. is a life sciences company based in Newburyport, Massachusetts, focused on developing device-based therapies for neurodegenerative diseases. The company specializes in the delivery and monitoring of cerebrospinal fluid (CSF) and has created a proprietary therapeutic platform aimed at removing toxic proteins from the CSF. EnClear's products are primarily designed to improve the lives of patients suffering from conditions such as Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). By providing innovative solutions in the treatment of these neurological diseases, EnClear Therapies aims to help halt disease progression and extend patient lifespans.
Volastra Therapeutics, Inc., a biotechnology company, develops therapies for the treatment of metastatic cancers. The company offers a library of organoids derived from metastatic cancer samples to elucidate how tumors spread and devise therapeutic strategies that target chromosomal instability during the process of cancer metastasis. Volastra Therapeutics, Inc. was incorporated in 2019 and is based in New York, New York.
Eyevensys S.A.S. develops non-viral gene therapy treatments for ophthalmology. The company’s develops Electro-Transfection (ET) of plasmids to the ciliary muscle therapy to deliver calibrated and sustained therapeutic proteins preferentially in the vitreous for several months. It develops an Electro-Transfection Injection System (ETIS) which is a drug device solution consisting of a device and a pulse generator. The company focuses on Uveitis, age-related macular degeneration (AMD), and retinopathies, including Central Retinal Vein Occlusion (RVO) and Diabetic Retinopathy (DR/DME). Eyevensys S.A.S. was incorporated in 2008 and is based in Paris, France.
Raziel Health, founded in 2012 and based in Rehovot, Israel, focuses on transforming healthcare delivery by providing accessible and cost-effective solutions for patients in their homes. The company integrates user-friendly technologies that enhance patient experiences and facilitate timely clinical interventions tailored to individual needs. By leveraging data analytics, Raziel Health supports wellness and disease management, aiming to improve health outcomes while making healthcare more affordable. In addition to its healthcare services, Raziel is developing RZL-012, a novel synthetic small molecule designed for obesity treatment, which works by inducing fat cell death at the injection site to reduce fat tissue.
Raziel Health, founded in 2012 and based in Rehovot, Israel, focuses on transforming healthcare delivery by providing accessible and cost-effective solutions for patients in their homes. The company integrates user-friendly technologies that enhance patient experiences and facilitate timely clinical interventions tailored to individual needs. By leveraging data analytics, Raziel Health supports wellness and disease management, aiming to improve health outcomes while making healthcare more affordable. In addition to its healthcare services, Raziel is developing RZL-012, a novel synthetic small molecule designed for obesity treatment, which works by inducing fat cell death at the injection site to reduce fat tissue.
Pi Therapeutics is a discovery-stage biopharmaceutical company aiming to develop a novel cancer drug. The company is financed by a syndicate of Takeda Pharmaceutical Company through its venture group Takeda Ventures Inc., Johnson & Johnson Innovation – JJDC, OrbiMed Israel Partners, Pontifax, and the Israel Innovation Authority, and has operated since March 2015 in the FutuRx biotech accelerator in Ness Ziona, Israel. The company’s mission is to develop novel first-in-class drugs directed against the ubiquitin-proteasome system (UPS), mainly for treatment of cancer.
Lyndra Therapeutics is a biotechnology company focused on developing ultra-long-acting oral medications designed to replace daily pill regimens. By providing sustained-release therapies that can be administered weekly or even monthly, the company aims to enhance medication adherence and improve health outcomes. Their innovative approach includes polypill strategies that consolidate multiple medications into a single dose, thereby increasing safety and efficacy while potentially reducing overall healthcare costs. Lyndra Therapeutics is actively developing treatments for a range of conditions, including Alzheimer's disease, cardiovascular and metabolic disorders, psychiatric conditions, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. Established in 2015 and headquartered in Watertown, Massachusetts, the company seeks to make a significant impact on global health through its advanced therapeutic solutions.
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel treatments for patients with hematological and musculoskeletal disorders that have significant unmet medical needs. The company's lead product candidate, KER-050, targets low blood cell counts, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis. Additionally, Keros is advancing KER-047, a small molecule therapeutic in Phase 1 clinical trials, aimed at treating anemia related to elevated hepcidin levels and fibrodysplasia ossificans progressiva. The company's third candidate, KER-012, focuses on disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, as well as pulmonary arterial hypertension. Founded in 2015 and based in Lexington, Massachusetts, Keros Therapeutics is recognized for its expertise in the role of the Transforming Growth Factor-Beta family of proteins, which regulate red blood cell and platelet production, along with muscle and bone maintenance.
Sitka Biopharma Inc. operates as a preclinical biotechnology company that focuses on developing a nanoparticle platform technology to enhance the absorption of drugs in difficult-to-penetrate tissues. Its development portfolio includes STK-01, a bladder cancer polymer drug delivery technology. The company was founded in 2013 and is based in Vancouver, Canada.
Canary Medical Inc. specializes in the development of medical implant and data management devices that facilitate remote patient monitoring and data collection. The company's primary innovation is the Canary Health Implantable Reporting Processor (CHIRP), a sensor-based device designed to gather and process medical data without requiring direct physician intervention. Additionally, Canary Medical creates smart medical devices that provide self-reports on patient activity, recovery, and treatment outcomes, thereby enhancing patient compliance. Established in 2013 and headquartered in Vancouver, Canada, the company has also formed a joint venture with BioScience Managers to launch CHARM Informatics, a platform aimed at collecting and monetizing data from implantable and wearable medical devices.
Canary Medical Inc. specializes in the development of medical implant and data management devices that facilitate remote patient monitoring and data collection. The company's primary innovation is the Canary Health Implantable Reporting Processor (CHIRP), a sensor-based device designed to gather and process medical data without requiring direct physician intervention. Additionally, Canary Medical creates smart medical devices that provide self-reports on patient activity, recovery, and treatment outcomes, thereby enhancing patient compliance. Established in 2013 and headquartered in Vancouver, Canada, the company has also formed a joint venture with BioScience Managers to launch CHARM Informatics, a platform aimed at collecting and monetizing data from implantable and wearable medical devices.
V-Wave Ltd. is a medical technology company based in Caesarea, Israel, with additional offices in the United States. Founded in 2009, it specializes in the development of percutaneous implantable therapeutic devices aimed at treating chronic heart failure (HF) patients, which is a major cause of morbidity and mortality worldwide. The company has created the V-Wave Shunt, a biocompatible inter-atrial unidirectional implant designed for patients with both preserved and reduced ejection fractions, addressing the needs of those who experience disabling symptoms despite optimal medical therapy. V-Wave's innovative approach focuses on relieving symptoms, reducing hospitalizations, enhancing exercise capacity, and improving overall quality of life for HF patients. The organization is backed by a team of experienced engineers and medical scientists who have a proven track record in developing and bringing various implantable cardiovascular devices to market.
ARTMS Products Inc. is a Vancouver-based company that specializes in manufacturing diagnostic imaging systems for the production and separation of medical isotopes. Founded in 2013, the company has developed the QUANTM Irradiation System, which facilitates decentralized and local production of critical isotopes such as gallium-68, zirconium-89, technetium-99m, and copper-64. ARTMS's primary offering, QUANTM99, is a system that combines hardware and consumables for the effective production of technetium-99m using medical cyclotrons. This innovative approach aims to enhance the accessibility and cost-effectiveness of medical isotopes, improving diagnostic imaging services.
Bioarray Therapeutics, Inc. is a biotechnology company founded in 2009, initially based in Boston and now located in Farmington, Connecticut. The company focuses on developing proprietary predictive diagnostic tests aimed at improving cancer treatment outcomes. Its primary product is a breast cancer response prediction test that utilizes gene expression profiling to evaluate a patient's likelihood of responding to standard pre-surgery taxane-based chemotherapy. By identifying the most effective treatment options based on genetic markers, Bioarray Therapeutics seeks to move away from the traditional trial-and-error approach in cancer care, enhancing the personalization of treatment for patients.
CathWorks Ltd. is a medical technology company based in Kfar-Saba, Israel, with an additional office in the United States. Founded in 2013, CathWorks specializes in developing advanced medical devices for the interventional cardiology market. The company's innovative technology leverages computational science and automatic multi-layered algorithms to enhance the utility of coronary angiography data, transforming visual assessments into objective decision-making tools for physicians. Its flagship product, CathWorks FFRangio, is a non-invasive device that provides objective multi-vessel physiological measurements, aimed at optimizing and confirming intra-procedural decisions for percutaneous coronary interventions (PCI). CathWorks is privately held and benefits from strong partnerships and support from leading venture capital firms in the medical devices sector.
Sitka Biopharma Inc. operates as a preclinical biotechnology company that focuses on developing a nanoparticle platform technology to enhance the absorption of drugs in difficult-to-penetrate tissues. Its development portfolio includes STK-01, a bladder cancer polymer drug delivery technology. The company was founded in 2013 and is based in Vancouver, Canada.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.
Physiq, Inc. is a health technology company based in Chicago, Illinois, that specializes in personalized physiology analytics through its cloud-based predictive platform. The company has developed VitaLink, a remote patient monitoring interface that equips clinicians with insights into the health status of patients with chronic illnesses while in an ambulatory setting. Its technology processes various data streams to establish an individual's normal baseline, enabling the detection of significant changes in vital signs that may indicate impending medical events. This personalized approach allows healthcare providers to manage patient care more effectively and empowers individuals to take charge of their health and fitness. Additionally, Physiq's platform can be integrated into monitoring devices from other manufacturers, enhancing their capabilities. Founded in 2013 and initially known as VGBio, Inc., Physiq operates in both regulated healthcare and the health and fitness markets.
PHEMI Systems Corporation specializes in developing a privacy, security, governance, and data management system tailored for Microsoft Azure. Founded in 2013 and based in Vancouver, Canada, the company provides the PHEMI Data Privacy Manager, a cloud-based solution designed for the healthcare sector. This system addresses the critical need for organizations to secure and govern access to privacy-sensitive information while facilitating compliance with privacy regulations. Optimized for Microsoft Azure, the software connects to numerous data sources and integrates seamlessly with popular data science and business analysis tools. Built on a privacy-by-design architecture, PHEMI Data Privacy Manager supports data sharing and offers a flexible usage-based pricing model, making it scalable for organizations of varying sizes.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.
Lyndra Therapeutics is a biotechnology company focused on developing ultra-long-acting oral medications designed to replace daily pill regimens. By providing sustained-release therapies that can be administered weekly or even monthly, the company aims to enhance medication adherence and improve health outcomes. Their innovative approach includes polypill strategies that consolidate multiple medications into a single dose, thereby increasing safety and efficacy while potentially reducing overall healthcare costs. Lyndra Therapeutics is actively developing treatments for a range of conditions, including Alzheimer's disease, cardiovascular and metabolic disorders, psychiatric conditions, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. Established in 2015 and headquartered in Watertown, Massachusetts, the company seeks to make a significant impact on global health through its advanced therapeutic solutions.
Biscayne Pharmaceuticals, Inc. is a biopharmaceutical company based in Miami, Florida, focused on developing therapies that leverage growth hormone-releasing hormone (GHRH) analogs. The company is engaged in creating GHRH antagonists aimed at treating various cancers, including castrate-resistant prostate cancer, and GHRH agonists intended for cardiac repair in patients with heart disease. Additionally, Biscayne Pharmaceuticals is involved in developing drugs for refractory epilepsy and drug-resistant cancer by targeting GHRH receptors, which play a critical role in stimulating growth hormone production for tissue growth and repair. Since its incorporation in 2012, the company has aimed to provide innovative treatments for patients with challenging medical conditions.
Biscayne Neurotherapeutics is a clinical-stage biotechnology company developing novel therapies for difficult-to-treat neurological disorders. Biscayne’s lead compound, BIS-001, is in clinical development for the treatment of refractory forms of epilepsy. Biscayne Neurotherapeutics has an experienced executive team with an extensive track record of successful drug development, and its scientific advisors include a number of highly respected experts studying seizure and other CNS disorders. The company is headquartered in Miami, Florida, and benefits from the growing entrepreneurial South Florida biomedical sector.
Microbion Corporation is a biopharmaceutical company that specializes in developing products for the treatment of resistant bacterial infections. The company focuses on bismuth-thiols, which are designed to address chronic and acute wound infections, prevent microbial biofilms on implanted medical devices, and manage biofilms in various infectious diseases. Additionally, Microbion creates therapeutics aimed at treating antibiotic-resistant microbes, including methicillin-resistant staphylococcus aureus, and targets conditions such as diabetic foot ulcers, orthopedic implant-related infections, and military wound-associated infections. Founded in 1982, Microbion is headquartered in Bozeman, Montana, with an additional office in Vancouver, Canada.
SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cell engineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges.
MSI Methylation Sciences Inc. is a biotechnology company based in Canada that focuses on developing oral and small molecule therapies for the adjunctive treatment of Major Depressive Disorder (MDD). Founded in 2007, the company is known for its flagship product, Strada, which is an orally administered therapy aimed at alleviating symptoms of depression in MDD patients. In addition to its therapeutic developments, MSI Methylation Sciences also markets S-Adenosyl Methionine, a prescription drug used as a dietary supplement. The company's work is centered around addressing mental health challenges through innovative treatment options.
Sitka Biopharma Inc. operates as a preclinical biotechnology company that focuses on developing a nanoparticle platform technology to enhance the absorption of drugs in difficult-to-penetrate tissues. Its development portfolio includes STK-01, a bladder cancer polymer drug delivery technology. The company was founded in 2013 and is based in Vancouver, Canada.